Research Report Explores The Smart Inhalers Market Will Be Valued At US$ 130 Mn By 2026
New York City, United States -- Since the COVID-19 infection flare-up in December 2019, the malady has spread to right around 100 nations around the world with the World Health Organization proclaiming it a general wellbeing crisis. The worldwide effects of the coronavirus sickness 2019 (COVID-19) are now beginning to be felt, and will essentially influence the Healthcare Industry in 2020.
The smart inhalers market is majorly driven by innovation, where the emphasis is on digital partnerships to offer smart inhaler products due to the increasing prevalence of respiratory disorders.
Partnerships, collaborations, and agreements between pharma and digital companies play a key role in the market’s supply chain. Increasing adoption of digitally-improved products across various end users is driving growth and innovation in the digital healthcare industry.
Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/26881
Company Profiles
- OPKO Health, Inc.
- AstraZeneca plc
- GlaxoSmithKline
- Propeller Health
- Aptar Pharma
- Novartis AG
- Boehringer Ingelheim
- Teva Pharmaceuticals
- H&T Presspart Manufacturing Ltd.
- Sensirion AG
- Cohero Health, Inc.
- Others.
Smart inhaler technology is rapidly becoming one of the most important areas of collaboration between pharma and digital health companies. A smart inhaler is now considered a part of the new-age digital technology, which is designed to improve disease management in respiratory diseases.
The leading manufacturers of smart inhalers are focusing on collaborating with digital and software companies in order to serve the targeted population. Moreover, such collaborations also help manufacturers launch their products more conveniently as well as enhance their distribution channels.
For instance, Propeller Health, a leading digital health solution provider for respiratory medicine, collaborated with Novartis AG to develop a custom add-on sensor for the Breezhaler inhaler, a smart inhaler used for COPD treatment. AstraZeneca plc formed a digital health partnership with the digital health company Adherium to manufacture smart inhalers.
In September 2017, Adherium announced the FDA approval for SmartTouch, a Symbicort inhaler for AstraZeneca’s Symbicort aerosol inhaler. All these factors are projected to drive the growth of the global smart inhalers market during the forecast period.
The growth of the smart inhalers market is attributed to the increasing prevalence of asthma and COPD across the globe. According to the latest research by the company, the global smart inhalers market is expected to account for revenue over US$ 130 Mn in terms of value by the end of 2026. The smart inhalers market is expected to witness rapid growth with a CAGR pegged at 12.2% through 2026. The smart inhalers market is moderately consolidated due to the presence of leading international players.
Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/26881
Regional Performance of the Smart Inhalers Market
The revenue from North America smart inhalers market is expected to expand at a significant CAGR and is estimated to remain a dominant regional market for smart inhalers. This is majorly due to the rising per capita income in North America which is driving individuals to spend more on health care.
This factor is expected to positively impact the growth in treatment options for respiratory disorders. Europe is also anticipated to be one of the leading regional markets for smart inhalers. India and China, along with other developing countries, have been preferable destinations for expenditure and investments.
The prime driving factors in the region are rapid industrialization, infrastructural developments, and economic growth. The growth in these regions is paving way for substantial growth opportunities for smart inhaler manufacturers.